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Abstract
Background: Many national antiretroviral therapy (ART) programmes encourage providers to identify and address
baseline factors associated with poor treatment outcomes, including modifiable adherence-related behaviours,
before initiating ART. However, evidence on such predictors is scarce, and providers judgement may often be
inaccurate. To help address this evidence gap, this observational cohort study examined baseline factors potentially
predictive of poor treatment outcomes in two ART programmes in South Africa, with a particular focus on
determinants of adherence.
Methods: Treatment-naïve patients starting ART were enrolled from a community and a workplace ART
programme. Potential baseline predictors associated with poor treatment outcomes (defined as viral load > 400
copies/ml or having discontinued treatment by six months) were assessed using logistic regression. Exposure
variables were organised for regression analysis using a hierarchical framework.
Results: 38/227 (17%) of participants in the community had poor treatment outcomes compared to 47/117 (40%)
in the workplace. In the community, predictors of worse outcomes included: drinking more than 20 units of
alcohol per week, having no prior experience of chronic medications, and consulting a traditional healer in the
past year (adjusted odds ratio [aOR] 15.36, 95% CI 3.22-73.27; aOR 2.30, 95%CI 1.00-5.30; aOR 2.27, 95% CI 1.00-5.19
respectively). Being male and knowing someone on ART were associated with better outcomes (aOR 0.25, 95%CI
0.09-0.74; aOR 0.44, 95%CI 0.19-1.01 respectively). In the workplace, predictors of poor treatment outcomes
included being uncertain about the health effects of ART and a traditional healer’s ability to treat HIV (aOR 7.53,
95%CI 2.02-27.98; aOR 4.40, 95%CI 1.41-13.75 respectively). Longer pre-ART waiting time (2-12 weeks compared to
<2 weeks) predicted better treatment outcomes (aOR 0.13, 95% CI 0.03-0.56).
Conclusion: Baseline predictors of poor treatment outcomes were largely unique to each programme, likely
reflecting different populations and pathways to HIV care. In the workplace, active promotion of HIV testing may
have extended ART to individuals who, without provider initiation, would not have spontaneously sought care. As
provider-initiated testing makes ART available to individuals less motivated to seek care, patients may need
additional adherence support, especially addressing uncertainty about the health benefits of ART.
Background
The global burden of HIV is heaviest in lower-income
countries where the majority of adults with HIV live [1].
H o w e v e rb y2 0 0 8o n l y4 2 %o ft h o s ei nn e e do fa n t i -
retroviral therapy (ART) worldwide were receiving
treatment [2]. The goal of ART is for patients to achieve
and maintain virological suppression for as long as pos-
sible. In many low-income countries, where access to
ART was very limited prior to the availability of highly
efficacious triple combination therapy, the most impor-
tant determinant of virological suppression is adherence
to clinical follow-up and to treatment [3-8]. Contrary to
initial scepticism, good treatment outcomes including
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were reported in early pilot ART programmes in lower-
income countries, compared to high-income country
programmes [6,9-11].
Despite these encouraging early results, declining
levels of adherence and poorer treatment outcomes have
been reported in some lower-income countries as ART
programmes have been scaled up [12-16]. Little is
known about the reasons for worsening outcomes in
these programmes, and since the majority of published
literature represents studies that are cross-sectional in
design, even less is known about baseline factors predic-
tive of poor treatment outcomes. Many ART guidelines
emphasise the need for providers to identify and address
risk factors for poor adherence, and providers routinely
use their own judgement, thought to be no better than
chance [17,18], to predict future adherence behaviours.
Given the importance of appropriately supporting
patients starting ART, it is vital to identify baseline
behavioural factors related to adherence that influence
poor treatment outcomes. In this cohort study we exam-
ined baseline factors potentially predictive of poor treat-
ment outcomes, defined as unsuppressed viral load and
complete discontinuation of clinical follow-up and treat-
ment, in two established programmes in South Africa,
one a community public-sector programme and one a
workplace-based programme. The focus was on factors
potentially influencing adherence to treatment and to
clinical follow-up, with a view to identifying individuals
who might benefit from more intensive adherence
support.
Methods
Setting
This study was conducted within two ART programmes
in South Africa. The first was a community programme
located within a tertiary public-sector hospital serving a
d i v e r s ep e r i - u r b a np o p u l a t i o ni nJ o h a n n e s b u r g .M o s t
patients self-presented for HIV treatment after under-
g o i n gv o l u n t a r yc o u n s e l l i n ga n dt e s t i n g( V C T )i nap r i -
mary health centre. HIV treatment and care, including
laboratory testing and treatment for opportunistic infec-
tions, were provided free of charge but patients were
expected to cover other expenses such as transport to
the clinic. Individuals were medically eligible for ART if
they were in WHO stage 4 and/or had a CD4 count of
<200 cells/mm
3. The first line ART regimen was d4T/
3TC/efavirenz (or nevirapine if efavirenz was
contraindicated).
The second study site was a workplace programme
located within a tertiary mining company hospital in
Northwest Province. Most patients were referred for
treatment after undergoing counselling and testing as
part of periodic VCT campaigns, yearly employment
health examinations or provider-initiated testing and
counselling (PITC). The hospital provided free HIV
treatment and care, including laboratory testing and
treatment for opportunistic infections, as well as free
transport to the clinic for mine employees. Individuals
were medically eligible for ART if they were in WHO
stage 4; or had a CD4 count of <250 cells/mm
3;o rw e r e
i nW H Os t a g e3w i t haC D 4c o u n t< 3 5 0c e l l s / m m
3.
The first line ART regimen was Combivir (AZT + 3TC)
and efavirenz (or nevirapine if efavirenz was
contraindicated).
Design and participants
This cohort study was conducted among consenting
individuals initiating ART in the two study sites. Partici-
pants had to be at least 18 years of age, ART naïve,
medically eligible for ART initiation, and willing to give
written informed consent for enrolment. In both sites,
clinic staff were asked to refer individuals presenting to
start ART to the research study staff. The clinic staff did
not collect information on the number of individuals
starting ART who were eligible for the study, nor those
among them who refused referral to the research staff.
Study procedures
At baseline, a semi-structured questionnaire taking
approximately 45 minutes was administered to partici-
pants at both sites to assess exposures potentially pre-
dictive of poor adherence. Participants were also asked
to provide contact information in case they missed the
study follow-up visit. Refusal to provide this information
was not an exclusion criterion. At the six-week pro-
gramme visit, participants were interviewed briefly for
an interim assessment of self-reported adherence. At the
six-month programme visit, conducted between 20 and
28 weeks after starting ART, a short questionnaire con-
cerning modifiable behavioural factors potentially related
to adherence was administered, and viral load measure-
ments were obtained from the clinical records. Those
who missed their six-month visit by one month or more
were classified as having discontinued care. They were
contacted using previously collected locator information,
and a semi-structured questionnaire was conducted to
ascertain treatment outcomes. This was done in person
whenever possible, but telephonically otherwise, to con-
firm reasons for discontinuation of care. All study inter-
views were conducted by a trained research nurse in the
participant’s preferred language (whether English or one
of the four main local languages).
Exposures of interest
The choice of exposures of interest assessed at baseline
was informed by preliminary pilot work conducted in
the workplace programme [19]. Exposure variables were
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work (see Figure 1), within which factors of interest
were grouped into three levels according to how directly
they were hypothesised to influence adherence
behaviour.
Outcome
In the primary analysis participants were classified as
having a poor treatment outcome if: (i) they attended
the six-month programme visit but had an HIV viral
load >400 copies/ml; or (ii) they missed the six-month
visit by one month or more, and upon tracing were
found to be alive but no longer taking ART.
Since our main interest was in factors affecting adher-
ence, individuals known to have died before six months
were excluded from the analysis. This is because early
mortality on ART is more likely due to advanced dis-
ease, and co-morbidity at baseline, than to poor
Figure 1 Hierarchical conceptual framework for logistic regression. An illustration of the hierarchical conceptual framework used to conduct
the risk factor analysis where factors of interest were organised into three levels according to how directly they were thought to influence
adherence behaviour.
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missed their six-month visit, but could not be traced to
confirm their treatment outcomes.
Sample size
Based on recruitment rates in the study programmes
prior to the start of the study, 400 patients was the max-
imum number of participants feasibly expected to be
recruited during the allotted study recruitment period.
The overall percentage of patients failing to achieve vir-
ological suppression at six months among ART patients
in the workplace programme was estimated at 37%
(Charalambous S, unpublished data). For an overall
power of 90% and a type 1 error of 5%, the sample size
of 400 would have enabled the detection of an odds
ratio of 4 for any risk factor with a prevalence of 10-
1 5 %a n da no d d sr a t i oo f3f o ra n yr i s kf a c t o rw i t ha
prevalence of 25-35% in the population. A sample size
of 300 would have enabled the detection of an odds
ratio of 4 for any risk factor with a prevalence of
15-35%.
Data analysis
Data analysis was performed with Stata 10 software
(Stata Corp., College Station, Texas, USA). The unad-
justed association of each factor with the outcome was
expressed as an odds ratio (OR) and its associated 95%
confidence interval (CI) and p-value from the chi-square
or Fisher’s exact test. Variables that showed evidence of
an association with the outcome in the univariable ana-
lysis (p < 0.2), and any a priori confounders, were exam-
ined in the multivariable analysis.
Logistic regression analysis was conducted to assess
associations between exposures of interest and the out-
come. Exposures of interest were analysed using a hier-
archical framework that grouped exposures into three
main levels: distal, intermediate and proximate, depend-
ing on how directly they were thought to influence the
outcome (see Figure 1 and Appendix 1). The framework
served to better organise the analysis in order to avoid
the misclassification of proximate factors as confounders
of the distal ones [22] and to enable the grouping of
similar variables into the same hierarchical level in
order to assess co-linearity. In the case of ordered cate-
gorical variables, departures from linearity were assessed
and, when appropriate, a test for linear trend was
conducted.
The multivariable model was constructed in three
stages. An initial model was constructed using distal
variables that showed evidence of an association with
the outcome in the univariable analysis (p < 0.2) and
age, considered as an ap r i o r iconfounder. Next, an
intermediate-level model was constructed by adding the
intermediate variables retained from the univariable
analysis. Lastly, the final model was constructed by add-
ing the proximate variables of interest. Explanatory vari-
ables were sequentially dropped within each group,
starting with variables with the weakest association with
the outcome, based on the likelihood ratio test. Only
variables associated with the outcome with p < 0.1 were
retained in each model.
A sensitivity analysis was conducted using the more
commonly used proxy measure of poor adherence, hav-
ing a viral load of >400 copies/ml, restricted to indivi-
duals with an available viral load result at the six-month
visit, in order to determine whether the models would
change when the outcome of discontinuing treatment
was excluded. A second sensitivity analysis was con-
ducted to test the effect of an alternative hierarchical
order than that employed in the primary conceptual fra-
mework. Variables strongly associated with the outcome
in the primary framework were moved from the distal
to the proximate level or vice-versa.
Ethics
The study was approved by the Research Ethics Com-
mittee of the University of KwaZulu-Natal, the Human
Ethics Research Committee of the University of Witwa-
tersrand, and the Ethics Committee of the London
School of Hygiene & Tropical Medicine, UK. Each parti-
cipant provided written informed consent for study
participation.
Results
Participants
Enrolment of study participants took place between May
2006 and February 2007. Follow-up continued until Sep-
tember 2007. During the study period the total number
of patients who started ART, irrespective of whether or
not they met the study eligibility criteria, was 550 in the
community programme and 216 in the workplace pro-
gramme. Of this population 267 and 144 participants
were enrolled into the study in the community and the
workplace respectively. The gender and age profiles of
the general patient population and of the study cohort
were similar. In the community, 64% of the general
patient population were female compared to 61% of
study participants, while the median age of the general
patient population was 38 years, compared to 37.5 years
for participants. In the workplace, 5% of both general
patient population and those enrolled were female,
while the median age in both groups was 46 years.
Figure 2 shows the construction of the study cohort.
Among those enrolled in the community programme,
40/267 (15%) were excluded from the risk factor analysis
mainly due to death and loss to follow up with
unknown treatment outcomes. In the workplace 27/144
(19%) were excluded, primarily because they could not
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pants agreed to provide contact information for later
tracing in case they missed the six-month visit.
Characteristics of the 227 community and 117 work-
place participants included in the risk factor analysis are
shown in Table 1. In the community programme the
median age was 37 years (interquartile range [IQR]
3 1 - 4 4 ) ,a n dt h em a j o r i t yw e r ef e m a l e( 6 7 % )a n du n e m -
ployed (71%), despite a median duration in education of
11 years (IQR 8-12). The median CD4 count at ART
start was 101 cells/mm
3. The 40 individuals in the com-
munity programme excluded from the risk factor analy-
sis were similar in age (median 38 years) and
educational level (median 11 years) to those included,
Figure 2 Cohort construction by programme. (i) Total number of individuals assessed for eligibility for enrolment in the cohort study; (ii)
proportion of those assessed enrolled in the cohort study in each site; (iii) proportion of enrolled participants included in the risk factor analysis
and their treatment outcomes; (iv) percentage excluded from the analysis and reasons for exclusion.
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baseline CD4 count (median 66 cells/mm
3). In the
workplace, only six (5.1%) were female. The median age
was 46 years (IQR 37-52), median duration in education
was seven years (IQR 3-9), and median CD4 count was
183 cells/mm
3. The 27 individuals excluded from the
risk factor analysis were similar to those included in age
(median 47 years), sex (none female), educational level
(median 4 years) and baseline CD4 count (median 162
cells/mm
3).
Outcome assessment
In the community programme six months after ART
start, 38/227 (16.7%) had poor treatment outcomes (Fig-
ure 2). This included 24 (10.6%) who did not achieve
virological suppression at six months and an additional
14 (6.2%) who discontinued treatment and care alto-
gether. By contrast, in the workplace programme 47/117
(40.2%) had poor treatment outcomes. This included 21
(18.0%) who did not achieve virological suppression and
26 (22.2%) who discontinued treatment.
Predictors of poor treatment outcomes
Table 2 shows the results of the univariable analysis
organised using the hierarchical conceptual framework
with exposures grouped into distal, intermediate and
proximate levels. Factors found to be associated with
increased odds of poor treatment outcomes (p < 0.2) in
the univariable analysis were largely unique to each pro-
gramme. At the distal level in the community pro-
gramme, these factors were being female, not knowing
someone on ART, reporting having been tested for HIV
without being informed, and high alcohol consumption.
In the workplace, these were fewer years of education, a
CD4 count at baseline of 100-200 cells/mm
3, not know-
ing anyone who died of HIV, and a delay of less than
two weeks between HIV diagnosis and ART initiation.
Dissatisfaction with programme services was associated
with poor treatment outcomes in both programmes. At
the intermediate level, factors associated with increased
odds of poor treatment outcomes in both programmes
were uncertainty regarding the existence of HIV and
one’s own status. However, the prevalence of these
beliefs was extremely low in the community programme.
At the proximate level, in the community programme,
not having been prescribed chronic treatments in the
past was associated with poor treatment outcomes. In
the workplace, uncertainty regarding the positive effects
of ART, non-disclosure of HIV status, belief that ART
can cure HIV and that ART adherence will be difficult,
and sharing of medicines with family and friends in the
past were associated with poor treatment outcomes.
The results of the logistic regression analysis are
shown in additional file 1 (table S1). In the community
programme, in the final model, in which proximate fac-
tors were adjusted for the confounding role of inter-
mediate and distal variables, factors associated with
better treatment outcomes were: being male (adjusted
[a] odds ratio [OR] 0.25, 95% CI 0.09-0.74) and knowing
someone on ART (aOR 0.44, 95% CI 0.19-1.01). Drink-
ing more than 20 units of alcohol per week, having no
prior experience of taking chronic medications, and con-
sulting a traditional healer in the past year were asso-
ciated with worse outcomes (aOR 15.36, 95%CI 3.22-
73.27; aOR 2.30, 95%CI 1.0-5.3; aOR 2.27, 95%CI 1.00-
5.19 respectively) (see Table S1).
In the workplace programme, factors associated with
poor treatment outcomes were: being uncertain regard-
ing a traditional healer’s ability to treat HIV (aOR 4.40,
95%CI 1.41-13.75); being uncertain about the health
effects of ART (aOR 7.53, 95%CI 2.02-27.98); and more
frequently sharing medicines with family and friends
(aOR 3.46, 95%CI 1.26-9.50). Having 2 weeks to 3
months pre-ART waiting time compared to having less
than 2 weeks pre-ART waiting time was associated with
better treatment outcomes (aOR 0.13, 95%CI 0.03-0.56)
(see Table S1).
Sensitivity analyses
In a sensitivity analysis restricted to individuals with a
viral load result at the six-month visit, and in which the
outcome was defined as a virall o a do f> 4 0 0c o p i e s / m l ,
the associations between exposures and the outcome
were generally similar in trend and magnitude to those
in the primary analysis for both programmes. However,
in the workplace, a pre-ART waiting time of less than
two weeks was more strongly associated with lack of vir-
ological suppression in the sensitivity analysis than with
the composite outcome of non-suppression and discon-
tinuation of treatment in the primary analysis (aOR
0.04, 95%CI 0.01-0.28; aOR 0.13, 95%CI 0.03-0.56
respectively).
Table 1 Distribution of selected variables at start of
antiretroviral therapy, by programme
Variable Community
n = 227
Workplace
n = 117
Female, n (%) 152 (67.0%) 6 (5.1%)
Age, median (IQR), in years 37 (31-44) 46 (37-52)
Education, median (IQR), in years 11 (8-12) 7 (3-9)
Unemployed, n (%) 161(70.9%) 2 (1.7%)
Clinic waiting time, median (IQR),
in hours
6 (4-7) 4 (4-5)
Time since HIV diagnosis, median (IQR),
in months
11.7 (4.4-37.0) 1.4 (0.7-11.9)
CD4 count at baseline, median (IQR)
in cells/mm
3
101 (46-154) 183 (125-237)
IQR = interquartile range
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discontinuation of follow-up and treatment six months post treatment initiation) on antiretroviral therapy in
community and workplace programmes
Variables of interest Community Workplace
n(%) poor
treatment
outcomes
Unadjusted
OR
95%
CI
p-
value
n(%) poor
treatment
outcomes
Unadjusted
OR
95% CI p-
value
Distal level
Sex
Female 29/152(19.1%) 1 - 0.10 0/6 (0%) 1 - .
Male 9/75 (12.0%) 0.58 0.26-
1.29
47/111(42.3%) . .
Age (years)
<35 18/96(18.8%) 1 - 0.63* 10/23(43.5%) 1 - 0.28*
34-45 11/81(13.6%) 0.68 0.30-
1.54
7/26(26.9%) 0.48 0.15-1.58
>45 9/50(18.0%) 0.95 0.39-
2.30
30/68(44.1%) 1.02 0.40-2.66
Education (years)
0-6 6/36(16.7%) 1 - 0.85* 31/55(56.4%) 1 - <0.001*
7-10 14/75(16.7%) 1.15 0.40-
3.28
11/45(24.4%) 0.25 0.11-0.59
>10 18/116(15.5%) 0.92 0.33-
2.52
5/17(29.4%) 0.32 0.10-1.04
Alcohol consumption/week (units)
No alcohol 27/183(14.8%) 1 - 0.02
† 29/69(42.0%) 1 - 0.87
1-20 units 6/32(18.8%) 1.33 0.50-
3.54
8/22(36.4%) 0.79 0.29-2.12
>21 units 5/11(45.5%) 4.81 1.37-
16.89
10/26(38.5%) 0.86 0.34-2.17
Time since first HIV test in community
programme (months)
a
<6 10/74(13.4%) 1 - 0.27* n.a. n.a. n.a. n.a.
6-24 10/72(13.9%) 1.03 0.40-
2.65
>24 18/81(22.2%) 1.82 0.78-
4.27
Time since first HIV test in workplace
programme (months)
a
<0.5 n.a. n.a. n.a. n.a. 10/19(52.6%) 1 - 0.02
0.5-3 13/47(27.7%) 0.34 0.11-1.04
>3 22/46(47.8%) 0.83 0.28-2.41
Know anyone who died of HIV
Yes 28/168(16.7%) 1 - 0.79 25/80(31.3%) 1 - <0.001
No/not sure 8/53(15.1%) 0.89 0.38-
2.09
22/36(61.1%) 3.46 1.52-7.85
Know someone on ART
No 26/144(19.6%) 1 - 0.18 25/57(43.9%) 1 - 0.33
Yes 12/94(12.8%) 0.60 0.29-
1.26
7/22(31.8%) 0.60 0.21-1.69
Informed that being tested for HIV
Yes 31/201(15.4%) 1 - 0.17 44/114(38.6%) 1 - .
No/not sure 7/26(26.9%) 2.02 0.78-
5.21
1/1(100.0%) . .
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tion of follow-up and treatment six months post treatment initiation) on antiretroviral therapy in community and
workplace programmes (Continued)
Satisfied with programme services
Agree or strongly agree 34/173(19.7%) 1 - 0.06
‡ 16/57(28.1%) 1 - 0.01
‡
Disagree or strongly disagree 0/16(0%) . . 6/8(75.0%) 7.78 1.40-
42.14
Don’t know 4/38(10.5%) 0.48 0.16-
1.45
25/52(48.1%) 2.37 1.10-5.25
Intermediate level
A healthy looking person can have HIV
Yes 32/206(15.5%) 1 - 0.15 22/80(27.5%) 1 - 0.001
Not/not sure 6/21(28.6%) 2.18 0.79-
6.03
22/34(64.7%) 4.83 2.05-
11.49
Belief in HIV existence
Yes 36/224(16.1%) 1 - 0.07
‡ 36/102(35.3%) 1 - 0.02
No/not sure 2/3(66.8%) 10.44 0.92-
118.25
11/14(78.6%) 6.72 1.76-
25.66
Belief in own HIV status
Yes 35/221(15.7%) 1 - 0.06
‡ 37/102(36.3%) 1 - 0.03
No/not sure 3/6(50.0%) 5.31 1.03-
27.41
10/15(66.7%) 3.51 1.12-
11.06
A traditional healer can treat HIV
Disagree/strongly disagree 24/149(16.1%) 1 - 0.76
‡ 17/63(27.0%) 1 - 0.01*
Agree/strongly agree 2/9(22.2%) 1.49 0.29-
7.60
10/18(55.6%) 3.38 1.14-
10.00
Not sure/don’t know 12/169(17.4%) left1.10 0.51-
2.35
20/36(55.6%) 3.38 1.43-8.00
Consulted traditional healer in past
year
No 25/170(14.7%) 1 - 0.15 22/60(36.7%) 1 - 0.43
Yes 13/56(23.2%) 1.75 0.83-
3.72
25/57(43.9%) 1.35 0.64-2.83
Proximate level
Effect of ART on health
Feel better 22/134(16.4%) 1 - 0.85 26/87(29.9%) 1 - <0.001
Not sure/don’t know 16/92(17.4%) 1.07 0.53-
2.17
21/30(70.0%) 5.47 2.21-
13.54
ART can cure HIV
No 23/153(15.0%) 1 - 0.33 21/65(32.3%) 1 - 0.06
Yes/not sure 15/74(20.3%) 1.44 0.70-
2.95
25/50(50.0%) 2.10 0.98-4.48
How difficult or easy will it be to
adhere?
Easy/very easy 36/197(18.3%) 1 - 0.08
‡ 24/76(31.6%) 1 - 0.01
Difficult/very difficult/not sure 2/30(6.7%) 0.32 0.07-
1.40
23/41(56.1%) 2.80 1.30-6.10
Disclosed HIV status
Yes 36/222(16.2%) 1 - 0.20
‡ 18/56(32.1%) 1 - 0.08
No 2/5(40.0%) 3.44 0.56-
21.35
29/60(49.3%) 1.97 0.93-4.20
Disclosed the initiation of ART
Yes 29/196(14.8%) 1 - 0.09 9/37(24.3%) 1 - 0.02
No 8/29(27.5%) 2.19 0.89-
5.42
38/80(47.5%) 2.81 1.17-6.71
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factors strongly predictive of poor treatment outcomes
were reclassified in the hierarchical framework to deter-
mine if and how this would affect the final models. In
the community programme, traditional medicine use
was reclassified as a distal factor while time since
known HIV status and knowing someone ART were
reclassified as intermediate factors. In the workplace
programme, beliefs regarding HIV and beliefs regarding
traditional medicines were reclassified as distal factors,
while CD4 count at baseline, knowing someone with
HIV and time of known HIV status were reclassified as
intermediate factors. There were no important differ-
ences between the final model obtained from the pri-
mary analysis and that obtained from the sensitivity
analysis in either programme (data not shown).
Discussion
After six months on ART, poor treatment outcomes
were more common among participants in the longer-
established and better-resourced workplace programme
than in the community programme. The predictors of
poor outcomes were largely unique to each programme,
with non-biomedical beliefs concerning HIV and ART
playing a larger role in the workplace programme than
in the community programme.
The workplace programme may have features in com-
mon with others that offer increased access to the
catchment ART population through robust VCT, PITC,
and the minimization of structural barriers known to
inhibit access to treatment. A paradoxical consequence
of the success in promoting HIV testing and facilitating
access to care in the workplace programme, such that
Table 2 Univariable level predictors of poor treatment outcomes (viral load >400 copies/ml and complete discontinua-
tion of follow-up and treatment six months post treatment initiation) on antiretroviral therapy in community and
workplace programmes (Continued)
Social support for taking ART
Yes 37/222(16.7%) 1 - 1.00
‡ 13/39(33.3%) 1 - 0.16
No/not sure 1/5(20.0%) 1.25 0.14-
11.50
20/41(48.8%) 1.90 0.77-4.71
Prior TB treatment
No 25/117(21.4%) 1 - 0.06 24/59(40.7%) 1 - 0.91
Yes 13/109(11.9%) 0.50 0.24-
1.03
8/19(42.1%) 1.06 0.37-3.03
Adherence to prior chronic treatment
Yes 16/135(11.9%) 1 - 0.06* 21/51(41.2%) 1 - 0.85
‡
No 7/29(24.1%) 2.40 0.87-
6.41
26/66(39.4%) 0.93 0.44-1.96 .
Not prescribed prior treatment 15/63(23.8%) 2.30 1.07-
5.07
0. .
Sharing medicines with family and
friends
Never/rarely 37/212(17.5%) 1 - 0.4
‡ 18/62(29.0%) 1 - 0.01
Sometimes/often/always 1/14(7.1%) 0.36 0.04-
2.87
25/47(53.2%) 2.78 1.26-6.14
Biological variables
CD4 count at baseline (cells/mm3)
<100 18/111(16.2%) 1 - 0.78* 8/24(33.3%) 1 - 0.10*
100-200 18/99(18.2%) 1.15 0.56-
2.35
24/46(52.2%) 2.18 0.78-6.09
>200 2/17(11.8%) 0.69 0.14-
3.28
15/47(31.9%) 0.94 0.33-2.67
Viral load at baseline (copies/ml)
<100,000 21/105(20.0%) 1 - 0.22 33/79(41.8%) 1 - 0.61
≥ 100,000 17/122(13.9%) 0.65 0.32-
1.31
14/38(36.8%) 0.81 0.37-1.80
OR: Odds ratio; CI: Confidence interval
*P value from likelihood ratio test
† P value for trend
‡P value from Fisher’s exact test
a Due to the large variation in the distribution of time since first HIV test between the two programmes this variable was categorised differently for each
programme.
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Page 9 of 14an estimated 95% of those eligible have started ART (C
Innes, personal communication), may partially explain
the poorer treatment outcomes observed. This approach
likely extended ART to a “second generation” [23,24] of
patients who, without the active promotion of PITC and
referral for treatment, may have been less motivated to
self-refer to these services. Uncertainty regarding the
health benefits of ART, previously reported to inhibit
adherence in other lower-income settings [25-30], was
prevalent and highly predictive of poor treatment out-
comes in the workplace. In this second generation of
potentially less well-motivated patients we can hypothe-
sise that beliefs regarding ART efficacy may play a larger
role in determining adherence than structural barriers,
which are critical among those who seek out treatment
more spontaneously in the community programme.
Among individuals entering care through PITC and
referral, there may be a need for more robust adherence
support focused not only on ameliorating structural bar-
riers to succeeding on treatment, but also on addressing
alternative beliefs regarding HIV and its treatment.
Uncertainty regarding ART benefits in the workplace
programme may also have been in part due to a
“healthy worker” effect such that workplace participants,
who were more likely to feel physically well, were also
more sceptical regarding the necessity for ART [31]. It
also may have reflected the surprisingly prevalent scepti-
cism regarding the existence of HIV altogether among
workplace participants [19], which could in part relate
to lower levels of education or the rural origin of many
employees, where alternative beliefs about disease causa-
tion may be more robust than in urban areas.
Positive attitudes towards the role of traditional hea-
lers, associated with poor adherence in other studies
from lower-income countries [13,32,33], were predictive
of poor treatment outcomes in both programmes. Seek-
ing advice or treatment from traditional healers is com-
monplace throughout Africa [34] and individuals
seeking health care may oscillate between representa-
tives of western biomedicine and traditional healers,
without much tension or sense of contradiction [35].
However, in the case of HIV treatment, both western
and traditional practitioners may be likely to advise their
patients to not mix ART with traditional medicines,
thereby leading some patients to discontinue ART either
temporarily or permanently. Given the ubiquitous role
of traditional healers in providing first-line care for
HIV-infected individuals, counselling paradigms must
evolve to include training for western medicine practi-
tioners on counselling patients regarding adherence to
ART even if they elect to seek alternative methods of
healing while on ART.
Past treatment-taking experience was predictive of
poor treatment outcomes in both programmes. In the
community programme, prior adherence to chronic
treatment predicted good treatment outcomes. Reported
adherence to prior chronic treatment may indicate an
increased level of self-efficacy regarding one’s own abil-
ity to adhere to long-term treatment, a factor previously
linked to better adherence [25,27,36,37]. In the work-
place programme, a history of treatment sharing with
family and friends was predictive of poor treatment out-
comes. Treatment sharing may have been more preva-
lent in this setting where family members had no
immediate access to the workplace ART programme.
Efforts in the workplace programme to increase ART
access to partners of ART patients may play an impor-
tant role in improving adherence.
In the workplace programme, starting ART less than
two weeks after being diagnosed with HIV was highly
predictive of poor treatment outcomes. Individuals who
started ART less than two weeks after HIV diagnosis
represented those who were referred to the HIV pro-
gramme for pre-ART counselling on the same day they
were tested for HIV or shortly thereafter, and were then
started on ART on the same day they were confirmed
to be eligible for treatment or shortly thereafter. Rapid
ART initiation partly reflects a strong commitment to
improving access to ART among those eligible for treat-
ment in the workplace programme. However, this study
highlights the challenge of providing adequate pre-ART
counselling support when individuals need to start ART
urgently (less than 2 weeks after HIV diagnosis). Thus,
in this and similar settings there may be a need for care-
ful balance between efforts to minimise delays in ART
initiation, once medically required, and allowing suffi-
cient time for the provision of adequate counselling and
adherence preparation.
Limitations
In the absence of a gold standard for measuring adher-
ence to ART, viral load was used as a proxy measure of
adherence. It remains possible for a limited number of
individuals to have been adherent to highly efficacious
ART regimens but to not have achieved virological sup-
pression at six months. However, the potential for this
to affect the estimate of adherence in this study was
limited by the fact that the cohort consisted of treat-
ment-naïve participants starting treatment at a time
when ART availability was restricted and among whom
transmitted resistance is unlikely [38-44]. In this popula-
tion, viral load was arguably the best measure of adher-
ence [4,5,45-48]. Participants were referred to the study
by clinic staff and we do not have information on the
number of people starting ART in the clinic who were
eligible for the study but refused referral. Therefore, we
cannot be certain that the prevalence of specific charac-
teristics is representative of all patients in the clinic who
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Page 10 of 14were eligible for the study. Nonetheless, the study analy-
sis compared data within the cohort and thus was valid
in ascertaining which characteristics were associated
with the outcomes observed. This is especially true con-
sidering that the refusal rates once patients were offered
study participation were very low (0% in the community
and 2% in the workplace programme). The programme-
specific analysis enabled the identification and the
exploratory comparison of several important and
strongly associated predictors of poor treatment out-
comes. While these findings allowed for a discussion of
the potential differences between predictors of adher-
ence in the two programmes, these differences were not
anticipated and thus the study was not designed nor
powered to compare them formally.
Conclusions
Poor treatment outcomes were more common in the
well-resourced workplace programme and largely pre-
dicted by different factors in comparison with the com-
munity programme. This difference reflects the potential
for the community programme to have a primarily self-
selected and hence a more motivated and a more adher-
ent patient population, among whom structural factors
are the main barriers to adherence and subsequent suc-
cess on treatment. In contrast, the workplace pro-
gramme may have a less selected, and hence less
motivated and less adherent patient population, among
whom non-biomedical beliefs of illness and treatment
play a larger role in predicting outcomes. In the work-
place and similar programmes in lower income-coun-
tries, where PITC extends ART to individuals
potentially less motivated to seek care, patients may
need additional adherence support, especially addressing
uncertainty about the health benefits of ART and how
to maintain adherence even if patients elect to seek
complementary methods of treatment. Meanwhile, in
the community programme and in others that are simi-
larly less focused on PITC, efforts to improve adherence
and retention should continue to prioritize addressing
structural barriers to treatment and increasing access to
ART to those currently unable to receive treatment.
Appendix 1: Description of hierarchical
framework used for organising the multivariable
regression analysis
In the hierarchical conceptual framework used to con-
duct multivariable analysis, factors of interest were orga-
nized into three levels according to how directly they
were thought to influence adherence behaviour [22].
Distal level exposures of interest were factors thought to
affect adherence behaviour indirectly or through other
mediating factors. These primarily included personal
characteristics and experiences of health-care services.
Intermediate level exposures of interest were factors
thought to mainly affect adherence through more proxi-
mate determinants. These intermediate level factors pri-
marily included factors related to beliefs regarding HIV
and traditional medicines. Finally proximate exposures
of interest were ones thought to more directly influence
adherence behaviour. This included factors related to
beliefs in ART, disclosure and adherence to prior
chronic treatment. This subdivision facilitated the orga-
nization of variables according to their theoretical hier-
archical relationship to each other and to the treatment
outcome. Organising variables using these theoretical
hierarchical relationships was deemed important for two
reasons: firstly, to avoid the misclassification of proxi-
mate factors as confounders of the distal determinants
and the reduction or nullification of the true effect of
the more distal determinants [22], and secondly, the
hierarchical classifications enabled the grouping of simi-
lar variables into the same hierarchical level in order to
facilitate the assessment of co-linearity among variables.
Steps in the multivariable analysis
Variables found to be associated with the outcome in the
univariable analysis (p < 0.2) and any potential confoun-
ders were further grouped into three hierarchical levels.
Figure 1 illustrates the hierarchical multivariable analysis
approach used to identify determinants of poor adherence
at each hierarchical level. Firstly distal level exposures of
interest were analysed, starting with a full model that
included all distal level exposures found to be associated
with the outcome in the univariable analysis (p < 0.2) and
any potential confounders. Explanatory variables were
then sequentially dropped from the model, starting with
variables with the weakest association with the outcome
based on the likelihood ratio test. Only variables found to
be associated with the outcome at a p-value smaller than
0.1 and a priori confounders were retained. Secondly, the
full intermediate level model included distal level determi-
nants identified in the previous model, intermediate level
exposures found to be associated with the outcome in the
univariable analysis (p < 0.2) and any ap r i o r iconfounders.
Finally at the proximate level, exposures of interest were
analysed starting with a full model that included distal
level determinants, intermediate level determinates, all
proximate level exposures found to be associated with the
outcome in the univariable analysis (p < 0.2) and any a
priori confounders.
At each level, variables thought to be highly correlated
within each group were cross-tabulated in order to
investigate co-linearity. Two tests for co-linearity, toler-
ance and variance inflation factor (VIF), were calculated
to test the strength of the interrelationships among the
variables. Tolerance is an indicator of how much co-lin-
earity a regression analysis can tolerate, while VIF is an
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error could be caused by co-linearity [49]. If co-linear
variables were identified, one variable, that with the
strongest association with outcome, was chosen to
represent the co-linear variables in the group.
Explanatory variables were then sequentially dropped
within each group, starting with variables with the weak-
est association with the outcome based on the likelihood
ratio test. Only variables found to be associated with the
outcome at a p-value < 0.1 were retained. This threshold
was chosen (as opposed to the more conventional 0.05)
to minimise the chances of erroneously excluding
potentially important risk factors [50,51]. However, the
interpretation of the models considered not only the
magnitude of the association (size of the odds ratios)
but also the precision of the point estimates (width of
the confidence intervals) [50]. The model presented is
the final model in which the effects of proximate vari-
ables are adjusted for the confounding role of distal and
intermediate variables.
Sensitivity analysis
Since there may be more than one logical way in which
variables could be grouped, a sensitivity analysis was
conducted to test the potential effect on regression ana-
lysis of employing an alternative hierarchical framework.
In this alternative conceptual framework, key factors
associated with poor adherence in the primary regres-
sion analysis were reclassified at different levels in the
hierarchy to test if and how this would change the mod-
els obtained from the primary regression analysis. For
example, beliefs in HIV and traditional medicines were
reclassified as distal factors, and factors related to edu-
cation and to income were reclassified as intermediate
factors. Factors related to beliefs regarding ART and
experience with chronic medications remained classified
as proximate factors.
Additional material
Additional file 1: Table S1: Baseline predictors of poor treatment
outcomes (viral load >400 copies/ml and complete discontinuation
of follow-up and treatment six months post treatment initiation) on
antiretroviral therapy: univariable and multivariable adjusted
models. Table S1 shows the multivariable adjusted analysis of baseline
variables associated with poor treatment outcomes (VL >400 copies/ml
or complete discontinuation of follow-up and treatment) after six
months of treatment. The multivariable analysis was conducted using a
hierarchical framework that grouped exposures into three main levels:
distal, intermediate and proximate, depending on how directly they were
thought to influence the outcome. The framework served to better
organise the analysis in order to avoid the misclassification of proximate
factors as confounders of the distal ones, and to enable the grouping of
similar variables into the same hierarchical level in order to assess co-
linearity.
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